Apimeds Pharmaceuticals US, Inc. (APUS) Income Statement
APUS 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsAPUS revenue and net income
APUS growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
APUS quarterly EPS vs estimates
Apimeds Pharmaceuticals US beat the analyst EPS estimate in 0 of the last 1 quarters. Next report: November 11, 2026.
APUS income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $5,706 | — | — | — | — |
| Gross profit | −$5,706 | — | — | — | — |
| Research & development | $1.6M | $0 | $98,544 | $368,000 | $489,939 |
| Sales, general & admin | $10.3M | $1.3M | $648,892 | $271,529 | $529,555 |
| Total operating expenses | $11.9M | $1.3M | $747,436 | $639,529 | $1.0M |
| Operating income | −$11.9M | −$1.3M | −$747,436 | −$639,529 | −$1.0M |
| Interest income | $107,595 | $2,824 | $7,811 | $0 | — |
| Interest expense | $283,011 | $117,719 | $38,069 | $29,137 | $6,740 |
| Income before taxes | −$6.0M | −$1.4M | −$777,694 | −$668,666 | −$1.0M |
| Net income | −$6.0M | −$1.4M | −$777,694 | −$668,666 | −$1.0M |
| EBITDA | −$5.7M | −$1.3M | −$739,625 | −$639,529 | −$1.0M |
| EPS (diluted) | −$1.37 | −$10.95 | −$6.13 | −$5.27 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $20,044 | — | $1,489 | — | — | — | — | — | — | — | — |
| Gross profit | — | −$20,044 | — | −$1,489 | — | — | — | — | — | — | — | — |
| Research & development | $959,742 | $901,144 | $361,104 | $619,693 | $651,784 | $0 | $0 | $0 | $0 | $0 | $28,551 | $3,000 |
| Sales, general & admin | $5.3M | $11.3M | $6.7M | $1.2M | $2.0M | $364,368 | $275,613 | $299,999 | $427,757 | $271,726 | $530,520 | $107,157 |
| Total operating expenses | $6.3M | $4.1M | $7.0M | $1.8M | $2.7M | $364,368 | $275,613 | $299,999 | $427,757 | $271,726 | $559,071 | $104,157 |
| Operating income | −$6.3M | −$4.1M | −$7.0M | −$1.8M | −$2.7M | −$364,368 | −$275,613 | −$299,999 | −$427,757 | −$271,726 | −$559,071 | −$104,157 |
| Interest income | $21,764 | $7 | $35,919 | $56,426 | $15,247 | $3 | $30 | $116 | $517 | $2,161 | — | — |
| Interest expense | $3.2M | $859,405 | $215,624 | $6,301 | $23,054 | $38,032 | $36,050 | $32,638 | $22,123 | $26,908 | $13,478 | $8,091 |
| Income before taxes | −$20.2M | −$35.1M | −$1.2M | −$1.8M | −$2.7M | −$402,397 | −$311,633 | −$332,521 | −$449,363 | −$296,473 | −$566,966 | −$110,020 |
| Net income | −$20.2M | −$35.1M | −$1.2M | −$1.8M | −$2.7M | −$402,397 | −$311,633 | −$332,521 | −$449,363 | −$296,473 | −$566,966 | −$110,020 |
| EBITDA | −$16.9M | −$34.2M | −$935,683 | −$1.8M | −$2.6M | −$364,365 | −$275,583 | −$299,883 | −$427,240 | −$269,565 | −$553,488 | −$101,929 |
| EPS (diluted) | −$11.77 | −$22.60 | −$0.92 | −$0.14 | −$0.26 | −$0.05 | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in APUS's financial statements (latest annual report filed May 4, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
APUS financial results
Apimeds Pharmaceuticals US reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $6.0 million. Diluted earnings per share came to −$1.37.
See the APUS stock overview for the latest quote and news, or the APUS chart for price history and technical indicators.
APUS income statement FAQ
Does Apimeds Pharmaceuticals US have revenue?
Apimeds Pharmaceuticals US reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Apimeds Pharmaceuticals US profitable?
No. Apimeds Pharmaceuticals US reported a net loss of $6.0 million in fiscal 2025.
How much does Apimeds Pharmaceuticals US spend on research and development?
Apimeds Pharmaceuticals US spent $1.6 million on research and development in fiscal 2025.
What are Apimeds Pharmaceuticals US's earnings per share?
Apimeds Pharmaceuticals US earned $-1.37 per diluted share in fiscal 2025, compared with $-10.95 a year earlier.
When will Apimeds Pharmaceuticals US report its next earnings?
Apimeds Pharmaceuticals US is expected to report results for the quarter ending September 30, 2026 on November 11, 2026.
When does Apimeds Pharmaceuticals US's fiscal year end?
Apimeds Pharmaceuticals US's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on May 4, 2026.